FindTrial
Sign In

KEYTRUDA ®( Pembrolizumab)

DRUG4 trials

Sponsors

Antengene Therapeutics Limited, Flare Therapeutics Inc., Krystal Biotech, Inc., HC Biopharma Inc.

Conditions

Advanced CancerAdvanced Urothelial CarcinomaCancerCutaneous MelanomaLocally Advanced or Metastatic Solid TumorsMelanoma Stage IIIMelanoma Stage IVOpen Label

Phase 1

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
RecruitingNCT05205109
Antengene Therapeutics LimitedLocally Advanced or Metastatic Solid Tumors
Start: 2022-06-07End: 2028-02-28Target: 98Updated: 2025-06-09
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
RecruitingNCT05929235
Flare Therapeutics Inc.Advanced Urothelial Carcinoma, Open Label, Oral Drug Administration
Start: 2023-08-24End: 2028-01-30Target: 120Updated: 2026-01-30
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RecruitingNCT05970497
Krystal Biotech, Inc.Cancer, Cutaneous Melanoma, Melanoma Stage III +1
Start: 2023-10-31End: 2027-07-31Target: 240Updated: 2025-05-18
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
RecruitingNCT06963814
HC Biopharma Inc.Advanced Cancer
Start: 2025-07-04End: 2027-05-30Target: 252Updated: 2025-07-17

Related Papers

A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial.
2026-02-28
A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01.
Journal of Clinical Oncology2025-05-282 citations
PPARG protein expression in advanced urothelial carcinoma and selection for response to FX-909, a first-in-class PPARG-targeting agent.
Journal of Clinical Oncology2025-02-10
Abstract A024: Genomic peroxisome proliferator-activated receptor gamma (PPARG) study: A sponsored testing program to identify patients harboring genetic alterations in advanced UC in support of the FX-909 Phase 1 study
Clinical Cancer Research2024-05-172 citations
A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma.
Journal of Clinical Oncology2024-01-294 citations